Key result
Patients with severely reduced EF ≤30% had a higher risk of death and HF hospitalization at 12 months compared to EF 31-40%.
Why the study?
The clinical profile and health care costs of patients hospitalized with heart failure and severely reduced ejection fraction who do not meet thresholds for advanced therapies are not well described in US practice.
Does severely reduced EF (≤30%) compared to EF 31-40% worsen postdischarge outcomes and increase healthcare costs in patients hospitalized for worsening chronic HFrEF?
Observational (n=113,348)
Yes
Does severely reduced EF (≤30%) compared to EF 31-40% worsen postdischarge outcomes and increase healthcare costs in patients hospitalized for worsening chronic HFrEF?
Answers are grounded in this paper and cite their sources.
Patients with severely reduced EF (≤30%) hospitalized for worsening HF have higher 12-month mortality and HF hospitalization risks compared to those with EF 31-40%, despite higher GDMT utilization.
Background Many patients with heart failure (HF) have severely reduced ejection fraction but do not meet threshold for consideration of advanced therapies (ie, stage D HF). The clinical profile and health care costs associated with these patients in US practice is not well described. Methods and Results We examined patients hospitalized for worsening chronic heart failure with reduced ejection fraction ≤40% from 2014 to 2019 in the GWTG‐HF (Get With The Guidelines‐Heart Failure) registry, who did not receive advanced HF therapies or have end‐stage kidney disease. Patients with severely reduced EF defined as EF ≤30% were compared with those with EF 31% to 40% in terms of clinical profile and guideline‐directed medical therapy. Among Medicare beneficiaries, postdischarge outcomes and health care expenditure were compared. Among 113 348 patients with EF ≤40%, 69% (78 589) had an EF ≤30%. Patients with severely reduced EF ≤30% tended to be younger and were more likely to be Black. Patients with EF ≤30% also tended to have fewer comorbidities and were more likely to be prescribed guideline‐directed medical therapy (“triple therapy” 28.3% versus 18.2%, P <0.001). At 12‐months postdischarge, patients with EF ≤30% had significantly higher risk of death (HR, 1.13 [95% CI, 1.08–1.18]) and HF hospitalization (HR, 1.14 [95% CI, 1.09–1.19]), with similar risk of all‐cause hospitalizations. Health care expenditures were numerically higher for patients with EF ≤30% (median US$22 648 versus $21 392, P =0.11). Conclusions Among patients hospitalized for worsening chronic heart failure with reduced ejection fraction in US clinical practice, most patients have severely reduced EF ≤30%. Despite younger age and modestly higher use of guideline‐directed medical therapy at discharge, patients with severely reduced EF face heightened postdischarge risk of death and HF hospitalization.
No takes yet. Share an insight, caveat, or question.
Harrington et al. (2023) conducted an observational in Heart failure with reduced ejection fraction (n=113,348). Severely reduced EF (≤30%) vs. EF 31% to 40% was evaluated on Death at 12-months postdischarge (HR 1.13, 95% CI 1.08-1.18). Patients with severely reduced EF ≤30% had a higher risk of death and HF hospitalization at 12 months compared to EF 31-40%.
Synapse has enriched 10 related papers. Consider them for comparative context: